國家衛生研究院 NHRI:Item 3990099045/11982
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 857777      Online Users : 810
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version


    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/11982


    Title: Metformin reduces risk of benign nodular goiter in patients with type 2 diabetes mellitus
    Authors: Tseng, CH
    Contributors: National Institute of Environmental Health Sciences
    Abstract: Background: Whether metformin might affect the risk of benign nodular goite r in patients with type 2 diabetes mellitus has not been investigated. M ethods: Patients with new-onset type 2 diabetes mellitus during 1999-2005 were enrolled from Taiwan's National Health Insurance database. Analyses were conducted in a propensity score matched-pairs of 20,048 ever users and 20,048 never users of metformin. The patients were followed until December 31, 2011, for the incidence of benign nodular goiter. Hazard ratios were estimated by Cox regression incorporated with the inverse probability of treatment weighting using the propensity score. Results: Among the never users and ever users of metformin, 392 and 221 cases were diagnosed of benign nodular goiter during follow-up, with incidence of 457.88 and 242.45 per 100,000 person-years, respectively. The overall hazard ratio for ever versus never users was 0.527 (95% confidence interval: 0.447-0.621). When cumulative duration of metformin therapy was divided into tertiles, the hazard ratios for the first (<25.3 months), second (25.3-57.3 months) and third (>57.3 months) tertiles were 0.815 (0.643-1.034), 0.648 (0.517-0.812) and 0.255 (0.187-0.348), respectively. Sensitivity analyses estimating the overall hazard ratios for patients enrolled in each specific year from 1999 to 2005 consistently showed a lower risk of benign nodular goiter among users of metformin. Conclusion: Metformin use is associated with a lower risk of benign nodular goiter in patients with type 2 diabetes mellitus.
    Date: 2019-06
    Relation: European Journal of Endocrinology. 2019 Jun;180(6):365-372.
    Link to: http://dx.doi.org/10.1530/eje-19-0133
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0804-4643&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000468743400006
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85066163907
    Appears in Collections:[Others] Periodical Articles

    Files in This Item:

    File Description SizeFormat
    ISI000468743400006.pdf364KbAdobe PDF252View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback